This article is more than 5 years old. Information may no longer be current.
Ciliary neurotrophic factor yields macular thickness change in eyes with retinitis pigmentosa
Click Here to Manage Email Alerts
Change in macular thickness was identified as a dose-dependent response to a ciliary neurotrophic factor implant in eyes with retinitis pigmentosa, according to a study.
Data were culled from the phase 2 Ciliary Neurotrophic Factor (CNTF)-3 and CNTF-4 clinical trials. Study investigators analyzed five patients from the CNTF-3 trial and three patients from the CNTF-4 trial. Mean patient age was 50 years.
Two patients from the CNTF-3 study received a low-dose CNTF implant (250 ng per million cells per 24 hours). Three patients from the CNTF-3 trial and all three patients in the CNTF-4 trial received a high-dose implant (800 ng per million cells per 24 hours).
Fourier-domain optical coherence tomography (FD-OCT) was used to evaluate macular thickness. FD-OCT imaging was undertaken preoperatively and up to 30 months after implantation to assess macular thickness. A 3% change in mean macular thickness was the benchmark for measurable change.
Among three patients in the CNTF-3 cohort who received a low-dose implant, mean change in mean macular thickness from baseline to 18 months was –4.47 µm to 6 µm.
Among the three patients in the CNTF-3 group who received a high-dose implant, mean macular thickness increased by 19.25 µm in one eye at 18 months. In the CNTF-4 group, mean macular thickness increased by 27.08 µm in one eye and by 31.36 μm in the fellow eye at 30 months.
“Amongst these three responsive high-dose implant eyes, overall thickening of the retina could not be attributed to any specific retinal layer,” the authors wrote.
Disclosure: The authors have no relevant financial disclosures.
Click Here to Manage Email Alerts